Role of MRD Status in Treatment Intensification or De-Escalation of Adjuvant Therapy

Panelists discuss how minimal residual disease (MRD) status, as detected through circulating tumor DNA (ctDNA) analysis, can guide personalized treatment decisions by identifying patients who may benefit from intensification of adjuvant therapy and those who could safely undergo de-escalation of treatment regimens.

EP: 1.The Role of ctDNA in CRC

EP: 2.BESPOKE: Study Design, Efficacy End Points, and Methods

EP: 3.Overview of BESPOKE Patient Characteristics

EP: 4.BESPOKE: Highlighting the Disease-Free Survival by ctDNA Status

EP: 5.BESPOKE: ctDNA Clearance During and After ACT

Now Viewing

EP: 6.Role of MRD Status in Treatment Intensification or De-Escalation of Adjuvant Therapy

Recent Videos